Tryptamine Therapeutics (ASX:TYP)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Tryptamine Therapeutics.
RELATED STOCKHEAD STORIES
Psilocybin can tackle brain injuries and binge eating, and these ASX companies are in the game
ASX healthcare leaders wear many hats in interconnected sector
ASX Quarterly Health Wrap: Bioxyne revenue up 77%, Radiopharm lists on Nasdaq
Tony’s Takeaway: New year nuggets for biotech-hungry investors
Health Check: Biotech partnership eyes Euro market expansion for Rett syndrome drug
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
Positive interim results for Tryptamine’s trial of oral psilocybin to treat IBS
Tryptamine’s psilocin infusion study reveals solid results in obese
Could Trump’s second act boost these ASX psychedelic stocks?
Tryptamine completes psilocin-based IV-infusion study in obese subjects
Tryptamine’s world-first psilocin based IV-infusion meets key objectives in phase 1b study
Biocurious: From drug prices to efficiency drives, ASX biotechs await the ‘Trumpcare’ health fallout
Health Check: Actinogen powers ahead with key Alzheimer’s disease trial
